Tariffs, MFN & FDA Delays: Why Biotech Is at Risk
Tariffs, MFN pricing, and FDA delays are colliding, and small biotech is paying the price. One company already collapsed. More could follow.
In this episode, we break down how Section 232 pharmaceutical tariffs, the push to codify Most Favored Nation (MFN) pricing, and new proposals in the FDA budget are reshaping biotech in real time.
The stakes are high. These policies don’t just exist on paper, they directly impact where drugs are developed, how capital flows, and whether small biotech companies survive.
We explore how tariffs could strain supply chains and smaller companies, how MFN could…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.